Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Roche is conducting a Phase 1/2 trial to evaluate Englumafusp Alfa in combination with Obinutuzumab and in combination with Glofitamab after a pre-dose of Obinu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Englumafusp Alfa
• Glofitamab (glofitamab)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING